US FDA approves AstraZenca’s Tagrisso drug as first-line treatment for lung cancer

Tagrisso will now be the first treatment doctors use on lung cancer patients whose tumours have a specific mutation called an EFGR mutation

More From BioPortfolio on "US FDA approves AstraZenca’s Tagrisso drug as first-line treatment for lung cancer"